Diagnostic-consultative center “Aleksandrovska” EOOD
- Address
- lock Available on a paid plan
Digestive System Diseases
Clinical research at Diagnostic-consultative center “Aleksandrovska” EOOD includes studies in Digestive System Diseases, with a strong focus on Crohn's disease. These trials are designed to evaluate new treatment options and better understand how therapies may improve disease control and intestinal health.
- Testing new therapies for Crohn's disease
- Assessing treatment effectiveness in Digestive System Diseases
- Studying responses to therapy in patients with inflammatory bowel conditions
The site is contributing to research that aims to improve care for people living with chronic digestive inflammation and to support more effective long-term management strategies.
Immune System Diseases
Another key area of work is Immune System Diseases, especially chronic spontaneous urticaria. The trials here are focused on evaluating whether new treatments can reduce symptoms such as hives and itch while also examining safety and overall tolerability.
- Investigating therapies for chronic spontaneous urticaria
- Measuring symptom improvement in immune-related skin conditions
- Checking safety and tolerability of emerging treatment options
These studies help advance care for patients whose immune-related symptoms can be persistent and difficult to manage.
Skin and Connective Tissue Diseases
Research in Skin and Connective Tissue Diseases at the Sofia site overlaps with immune-mediated skin disorders, particularly chronic spontaneous urticaria. The clinical trials are aimed at improving diagnostic understanding and testing whether new therapies can provide better relief from visible and uncomfortable skin symptoms.
- Evaluating treatments for hives without a known cause
- Exploring symptom relief in skin-related immune disorders
- Supporting better management of chronic skin conditions
With multiple investigators involved, the center is helping expand research options for patients affected by ongoing skin and connective tissue disease symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 23 therapeutic areas and 15 of 258 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 246 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 54 by active trials.
- 1Argenx5active
lock +53 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB12trials
lock +34 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic-consultative center “Aleksandrovska” EOOD
lock Showing 1 of 204 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 258 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Efgartigimod Alfa | 7 | Unknown | 2020-08-18 | 2025-04-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.